{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:59:26Z","timestamp":1791118766740,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>\n                      Mesenchymal stromal cells (MSCs) abrogate alloimmune response\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      , suggesting a novel cell-based approach in transplantation. Moving this concept toward clinical application in organ transplantation should be critically assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants &amp; measurements<\/jats:title>\n                    <jats:p>A safety and clinical feasibility study (ClinicalTrials.gov, NCT00752479) of autologous MSC infusion was conducted in two recipients of kidneys from living-related donors. Patients were given T cell\u2013depleting induction therapy and maintenance immunosuppression with cyclosporine and mycophenolate mofetil. On day 7 posttransplant, MSCs were administered intravenously. Clinical and immunomonitoring of MSC-treated patients was performed up to day 360 postsurgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Serum creatinine levels increased 7 to 14 days after cell infusion in both MSC-treated patients. A graft biopsy in patient 2 excluded acute graft rejection, but showed a focal inflammatory infiltrate, mostly granulocytes. In patient 1 protocol biopsy at 1-year posttransplant showed a normal graft. Both MSC-treated patients are in good health with stable graft function. A progressive increase of the percentage of CD4\n                      <jats:sup>+<\/jats:sup>\n                      CD25\n                      <jats:sup>high<\/jats:sup>\n                      FoxP3\n                      <jats:sup>+<\/jats:sup>\n                      CD127\n                      <jats:sup>\u2212<\/jats:sup>\n                      Treg and a marked inhibition of memory CD45RO\n                      <jats:sup>+<\/jats:sup>\n                      RA\n                      <jats:sup>\u2212<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell expansion were observed posttransplant. Patient T cells showed a profound reduction of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Findings from this study in the two patients show that MSC infusion in kidney transplant recipients is feasible, allows enlargement of Treg in the peripheral blood, and controls memory CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell function. Future clinical trials with MSCs to look with the greatest care for unwanted side effects is advised.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.04950610","type":"journal-article","created":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T23:51:15Z","timestamp":1286495475000},"page":"412-422","source":"Crossref","is-referenced-by-count":259,"title":["Autologous Mesenchymal Stromal Cells and Kidney Transplantation"],"prefix":"10.2215","volume":"6","author":[{"given":"Norberto","family":"Perico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Casiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Introna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Gotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Todeschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regiane Aparecida","family":"Cavinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Capelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cassis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Maras\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josee","family":"Golay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Noris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20230811","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1056\/NEJMon043418","article-title":"Transplantation 50 years later\u2013progress, challenges, and promises","volume":"351","author":"Sayegh","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-25-20230811","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/S0140-6736(07)60762-4","article-title":"Clinical update: Immunosuppression minimisation","volume":"369","author":"Sayegh","year":"2007","journal-title":"Lancet"},{"key":"R3-25-20230811","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/00007890-200205150-00005","article-title":"Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation","volume":"73","author":"Millan","year":"2002","journal-title":"Transplantation"},{"key":"R4-25-20230811","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jamcollsurg.2004.12.024","article-title":"Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath","volume":"200","author":"Shapiro","year":"2005","journal-title":"J Am Coll Surg"},{"key":"R5-25-20230811","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.tp.0000174341.49741.8f","article-title":"Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin","volume":"80","author":"Kirk","year":"2005","journal-title":"Transplantation"},{"key":"R6-25-20230811","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJMoa071074","article-title":"HLA-mismatched renal transplantation without maintenance immunosuppression","volume":"358","author":"Kawai","year":"2008","journal-title":"N Engl J Med"},{"key":"R7-25-20230811","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1098\/rstb.2001.0840","article-title":"Alloantigen-induced specific immunological unresponsiveness","volume":"356","author":"Wood","year":"2001","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"R8-25-20230811","doi-asserted-by":"crossref","first-page":"16885","DOI":"10.1073\/pnas.0407417101","article-title":"The molecular program induced in T cells undergoing homeostatic proliferation","volume":"101","author":"Goldrath","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-25-20230811","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/01.tp.0000284808.28353.2c","article-title":"Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury","volume":"84","author":"Ruggenenti","year":"2007","journal-title":"Transplantation"},{"key":"R10-25-20230811","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1681\/ASN.2006101143","article-title":"Regulatory T cells and T cell depletion: Role of immunosuppressive drugs","volume":"18","author":"Noris","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R11-25-20230811","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/ndt\/gfn778","article-title":"The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients","volume":"24","author":"Sewgobind","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R12-25-20230811","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1681\/ASN.2007020151","article-title":"Frontiers in nephrology: T cell memory as a barrier to transplant tolerance","volume":"18","author":"Valujskikh","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R13-25-20230811","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1432-2277.2008.00786.x","article-title":"Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation","volume":"22","author":"Crop","year":"2009","journal-title":"Transpl Int"},{"key":"R14-25-20230811","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2249.2009.03874.x","article-title":"Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells","volume":"156","author":"English","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"R15-25-20230811","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2002-07-2104","article-title":"Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide","volume":"101","author":"Krampera","year":"2003","journal-title":"Blood"},{"key":"R16-25-20230811","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/blood-2007-10-119370","article-title":"Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses","volume":"112","author":"Karlsson","year":"2008","journal-title":"Blood"},{"key":"R17-25-20230811","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.4049\/jimmunol.181.6.3933","article-title":"Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells","volume":"181","author":"Casiraghi","year":"2008","journal-title":"J Immunol"},{"key":"R18-25-20230811","first-page":"717","article-title":"Review of mesenchymal stem cells and tumors: executioner or coconspirator?","volume":"24","author":"Feng","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"R19-25-20230811","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/cncr.25056","article-title":"Human mesenchymal stem cells and their use in cell-based therapies","volume":"116","author":"Motaln","year":"2010","journal-title":"Cancer"},{"key":"R20-25-20230811","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4049\/jimmunol.0900803","article-title":"Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes","volume":"183","author":"Fiorina","year":"2009","journal-title":"J Immunol"},{"key":"R21-25-20230811","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1634\/stemcells.2005-0620","article-title":"Sarcoma derived from cultured mesenchymal stem cells","volume":"25","author":"Tolar","year":"2007","journal-title":"Stem Cells"},{"key":"R22-25-20230811","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1158\/0008-5472.CAN-07-2665","article-title":"Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: A model of age-related tumorigenesis in mice","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res"},{"key":"R23-25-20230811","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/sj.bmt.1705798","article-title":"Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts","volume":"40","author":"Capelli","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R24-25-20230811","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14653240902960437","article-title":"The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs","volume":"11","author":"Capelli","year":"2009","journal-title":"Cytotherapy"},{"key":"R25-25-20230811","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2215\/CJN.01841105","article-title":"Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-25-20230811","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2217\/14622416.8.9.1127","article-title":"C-440T\/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation","volume":"8","author":"Baldelli","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R27-25-20230811","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"R28-25-20230811","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V62257","article-title":"Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate","volume":"6","author":"Gaspari","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R29-25-20230811","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cellimm.2007.07.004","article-title":"Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells","volume":"247","author":"Nowacki","year":"2007","journal-title":"Cell Immunol"},{"key":"R30-25-20230811","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"R31-25-20230811","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/jcb.21714","article-title":"Acidic pH stimulates the production of the angiogenic CXC chemokine, CXCL8 (interleukin-8), in human adult mesenchymal stem cells via the extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and NF-kappaB pathways","volume":"104","author":"Bischoff","year":"2008","journal-title":"J Cell Biochem"},{"key":"R32-25-20230811","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1016\/j.chroma.2009.03.068","article-title":"Determination of thromboxanes, leukotrienes and lipoxins using high-temperature capillary liquid chromatography-tandem mass spectrometry and on-line sample preparation","volume":"1216","author":"Dahl","year":"2009","journal-title":"J Chromatogr A"},{"key":"R33-25-20230811","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/cdd.2009.74","article-title":"IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: Implications for bone remodeling","volume":"16","author":"Huang","year":"2009","journal-title":"Cell Death Differ"},{"key":"R34-25-20230811","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14653240903193806","article-title":"Mesenchymal stem cells in hematopoietic stem cell transplantation","volume":"11","author":"Battiwalla","year":"2009","journal-title":"Cytotherapy"},{"key":"R35-25-20230811","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbmt.2010.03.017","article-title":"Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft versus host disease in a pediatric population","volume":"16","author":"Lucchini","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R36-25-20230811","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jcp.20959","article-title":"From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells","volume":"211","author":"Giordano","year":"2007","journal-title":"J Cell Physiol"},{"key":"R37-25-20230811","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3109\/14653240903253857","article-title":"Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury\/paraplegia: A pilot clinical study","volume":"11","author":"Pal","year":"2009","journal-title":"Cytotherapy"},{"key":"R38-25-20230811","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/stem.68","article-title":"Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans","volume":"27","author":"Sun","year":"2009","journal-title":"Stem Cells"},{"key":"R39-25-20230811","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/mt.2010.99","article-title":"Defining the probability that a cell therapy will produce a malignancy","volume":"18","author":"Prockop","year":"2010","journal-title":"Mol Ther"},{"key":"R40-25-20230811","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.yexcr.2010.02.016","article-title":"Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells","volume":"316","author":"Garcia","year":"2010","journal-title":"Exp Cell Res"},{"key":"R41-25-20230811","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1158\/0008-5472.CAN-10-1305","article-title":"Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: Putting the research field on track \u2013 letter","volume":"70","author":"Torsvik","year":"2010","journal-title":"Cancer Res"},{"key":"R42-25-20230811","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1634\/stemcells.2005-0298","article-title":"Mesenchymal stem cells and adipogenesis in hemangioma involution","volume":"24","author":"Yu","year":"2006","journal-title":"Stem Cells"},{"key":"R43-25-20230811","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood.V99.10.3838","article-title":"Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli","volume":"99","author":"Di Nicola","year":"2002","journal-title":"Blood"},{"key":"R44-25-20230811","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.smim.2007.10.004","article-title":"T cell immune reconstitution following lymphodepletion","volume":"19","author":"Williams","year":"2007","journal-title":"Semin Immunol"},{"key":"R45-25-20230811","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/j.1600-6143.2009.02721.x","article-title":"Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance","volume":"9","author":"Ge","year":"2009","journal-title":"Am J Transplant"},{"key":"R46-25-20230811","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1016\/j.transproceed.2009.08.072","article-title":"Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion","volume":"41","author":"Wang","year":"2009","journal-title":"Transplant Proc"},{"key":"R47-25-20230811","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"key":"R48-25-20230811","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.trim.2008.08.004","article-title":"Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate","volume":"20","author":"Popp","year":"2008","journal-title":"Transpl Immunol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201102000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:40:19Z","timestamp":1786369219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201102000-00025"}},"subtitle":["A Pilot Study of Safety and Clinical Feasibility"],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.04950610","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}